Objective-To determine whether in patients presenting with posturally related syncope administration of salt increases plasma volume and improves orthostatic tolerance. Patients with poor tolerance of orthostatic stress tend to have lower than average plasma and blood volumes. Design-A double blind placebo controlled study in 20 patients and an open study in 11 of the effects of giving 120 mmoUday of sodium chloride. Patients-31 patients presenting with episodes of syncope who had no apparent cardiac or neurological disease. Plasma volume was determined by Evans blue dye dilution, orthostatic tolerance by time to presyncope in a test of combined headup tilt and lower body suction, and baroreceptor sensitivity by the effect of neck-suction on pulse interval. Results-8 weeks after treatment, 15 (70%) of the 21 patients given salt and three (30%) of the placebo group showed increases in plasma and blood volumes and in orthostatic tolerance, and decreases in baroreceptor sensitivity. Improvement was related to initial salt excretion in that patients who responded to salt had a daily excretion below 170 mmol. The patients in the placebo group who improved also showed increases in salt excretion. Conclusions-In patients with unexplained syncope who had a relatively low salt intake administration of salt increased plasma volume and orthostatic tolerance, and in the absence of contraindications, salt is suggested as a first line of treatment.
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(Heart 1996;75:134-140) Keywords 4 We have recently introduced a test that combines head-up tilting with lower body suction. 5 We believe that this test, which causes progressive reduction in venous return and cardiac output, has a sound physiological basis and we have shown that a stage of the test can be defined which provokes presyncope in only 20% of asymptomatic volunteers but 85% of patients with histories strongly suggestive of posturally related syncope.6 Furthermore, because this test is reproducible, it should be useful in detecting responses in individual patients to therapeutic interventions. Indeed we have already examined the effects of cardiac pacemakers using this test and shown that the time to presyncope was almost identical irrespective of whether or not the heart was being paced. 7 Treatment of attacks of unexplained syncope is generally unsatisfactory and reports of benefits are often contradictory. For example, treatment with f,-adrenoceptor blocking agents has been claimed by some8-'0 to relieve symptoms, but others have found no benefit or even an exacerbation of symptoms."1-'3 The benefits of other agents also seem uncertain. 14 One form of treatment which has sometimes been recommended to prevent syncope is giving dietary salt supplements.15 The rationale for this is that the body's sodium content determines the volume of the extracellular fluid, including that of the plasma. Lately, we found that a subject's orthostatic tolerance is highly significantly correlated with his plasma volume.'6 It is likely, therefore, that an increase in plasma volume would lead to an increase in orthostatic tolerance. The question remains whether in patients with unexplained syncope an increase in dietary salt intake does increase plasma volume. Reports based on animal studies'7 or human studies'8 indicate that salt loading is likely to increase plasma volume. However, there have been no objective studies of the effects of salt in patients with poor orthostatic tolerance and the aim of the present work was to examine, using a double blind protocol, whether salt loading increased both plasma volume and orthostatic tolerance.
Patients and methods
We studied a total of 31 clot. Then they were centrifuged and the concentration of dye in the serum was determined using a spectrophotometer (Pye Unicam, Cambridge) and compared with known concentrations of dye made in undiluted serum from the same patient. The theoretical concentration of dye in the plasma at the time of injection was calculated by reverse extrapolation of the log concentration decay curve. The total quantity of blood removed from each patient was about 30 ml and this was replaced by an equal volume of saline. The repeatability (95% tolerance limits) of the plasma volume estimates was ± 62 ml. 19 The haematocrit was determined by the microhaematocrit method from blood withdrawn immediately before the dye injection.20 Blood volume was calculated as: plasma volume/(1 -hematocrit). Mean corpuscular volume was estimated from the initial blood sample using a Coulter counter.
BARORECEPTOR SENSITIVITY
Subjects reclined supine and were fitted with four standard electrocardiogram leads. After 20 minutes' rest a neck chamber, constructed from thermoplastic,21 was fitted round the subject's neck. The subject held his breath in expiration and, after five seconds, a pressure of 0, -20, or -40 mm Hg was applied for a further five seconds, on two occasions at each pressure. Baroreflex sensitivity was taken as the slope of the maximal prolongation of RR interval of the electrocardiogram against applied chamber pressure. The repeatability of these estimates (95% tolerance limits) was ± 0 5 ms/mm Hg (± 8-5% of mean values).
ORTHOSTATIC TOLERANCE
We used the method recently developed and evaluated in our laboratory.5 6 Subjects rested supine for 20 minutes on a specially constructed tilt table with built-on lower body chamber. The subject was then tilted head-up by 60°for 20 minutes after which, while they were still tilted, lower body suction was applied to below the iliac crests at -20 and then -40 mm Hg for 10 minutes at each pressure. Blood pressure was recorded throughout the test from the brachial artery by an automatic sphygmomanometer (Infrasonde, Puritan-Bennett, California) and in a finger maintained at heart level by a Finapres monitor (Ohmeda, Wisconsin). Heart rate was determined from the electrocardiogram. The end point of the test and the measure of orthostatic tolerance was the onset of imminent syncope, seen as a fall in systolic blood pressure to 80 study mm Hg or less. The repeatability of this test (95% tolerance limits) is ± 2-5 min.
Results

DOUBLE BLIND STUDY
Twenty patients who had been shown to have poor orthostatic tolerance6 were randomly allocated to the salt and placebo groups (10 to each). The ages and heights of the patients in the salt and placebo groups (means (SD)) were 41-2 (4.1) and 46-1 (5-8) years and 171-4 (3-1) and 169-8 (2 8) cm. Other data are listed in the table. There were no significant differences between the groups in any of study the baseline data (Mann-Whitney U test, P > 0 05). fter
At the second assessment the group taking asma salt showed significant increases in body weight, plasma and blood volumes, orthostatic tolerance (assessed as the time to onset of syncope), and urinary sodium excretion (P < 0-05, Wilcoxon signed-rank test). They also showed a significant decrease in baroreceptor sensitivity. None of these variables changed significantly in the placebo group and all variables in the salt group that changed significantly from the baseline data showed changes ------------that were also significantly different from the corresponding changes in the placebo group (Mann-Whitney test, P < 0 05). The responses are compared in the table.
Responses in individual patients were regarded as significant if they changed beyond the 95% tolerance limits of the repeatability of i measurements. On this basis eight of the 10 ;tudy patients taking salt but only three of the 10 taking placebo showed significant increases in plasma and blood volumes; the other patients showed no significant responses (fig 1) . All the patients from both groups who showed increases in plasma and blood volumes also showed improved tolerance to the orthostatic stress test and decreases in baroreceptor sensitivity (fig 2) . The patients in whom the plasma and blood volumes did not change did not show changes in either orthostatic tolerance or baroreceptor sensitivity. The only difference seen between patients who did not respond to salt and those who did was that their baseline salt excretion was higher. The mean 24 hour Time to presyncope (minutes) Figure 3 Time course ofchanges in heart rate and systolic and diastolic blood pressures during the orthostatic stress test in the 21 patients who received salt. Results (means (SEM)) are oftests before (-) RESPONSES OF BLOOD PRESSURE AND HEART RATE Salt administration had no significant effect on the supine values of blood pressure or heart rate in either of the two groups of patients who were given salt. The mean values and SD in the 21 patients given salt, before and after 8 weeks of treatment were systolic pressure 110-6(106) and 113-1 (9-5)mmHg, diastolic pressure 60-8 (9 7) and 61-5 (7 5) mm Hg, heart rate 63-4 (11-8) and 63-7 (9 6) beats/min. Values of blood pressures in the head-up tilt position were significantly (P < 0-01) higher after salt administration but were unchanged by placebo. Figure 3 shows the values of heart rate and blood pressure throughout the test, before and after salt administration.
RELATIONS BETWEEN VARIABLES Figure 4 shows the relations between the changes in orthostatic tolerance and the change in baroreceptor sensitivity, with the change in plasma volume. This figure, which presents data from all groups of patients including the placebo group shows that all patients in whom plasma volume increased by over 90 ml had significant increases in orthostatic tolerance and significant decreases in baroreceptor sensitivity. Only one of the 13 patients in whom plasma volume changed by less than 90 ml showed an increase in orthostatic tolerance and a decrease in baroreceptor sensitivity. Figure 5 shows the influence of the baseline salt excretion on the responses of plasma volume and orthostatic tolerance in the 21 patients given salt. The patients in whom the baseline excretion was less than 170 mmol/24 h all showed increases in plasma volume and orthostatic tolerance. Those excreting more than 190 mmol/day did not show significant increases.
SYMPTOMATIC EFFECTS
Most of the patients who took the salt capsules in the double blind study initially experienced some nausea. In all but one this persisted for less than two weeks, and in no subject did it necessitate withdrawal from the trial. No patient experienced any problems in taking the slow release sodium chloride tablets that were used in the open study. All patients, from both studies in whom increases in plasma volume and orthostatic tolerance were observed, including the three patients taking placebo who also showed changes, claimed to be entirely free from symptoms at the time of the second study. On the other hand, all the patients in whom the test results were unchanged claimed to be unchanged symptomatically.
Discussion
The principal finding from this study was .-....................... ..... di"'l""'ll'll"I'l""'ll,,'l""'ll""I tolerance adds further support to our conclu-0 _ t patients given salt, 70% imnproved, whereas in The striking and consistent findings from those taking placebo 30% improved, this work were the associations between the Interestingly, the patient who showed the responses of plasma and blood volumes and largest change in the entire study was actually the changes in both orthostatic tolerance and one who was given placebo. However, it tran-baroreceptor sensitivity. These associations spired that this patient had changed her diet were seen in all groups of patients including spontaneously and had had a large increase in the three patients taking placebo who showed body weight as well as in plasma and blood increases in their volumes. This finding is volumes. She, and the other two patients in entirely compatible with our recent report whom plasma volume increased on placebo, showing a highly significant positive correlaalso showed increases in urinary sodium excre-tion in a large group of patients between tion at the second assessment and this indi-orthostatic tolerance and plasma volume and a cates that all three had increased their salt negative correlation with baroreceptor sensi- ,hould result in an orthostatic stress should be determined and, ic tolerance. This is unless the sodium excretion is high (> 170 ;es in plasma volume mmol/day), oral salt administration should be in patients complain-given. The advantages of this simple treatment )pe. However, these are, firstly, that it is effective in people secreting Aith previous reports low levels of salt and secondly, it is safe; we following prolonged did not observe any adverse reactions. There :reases in plasma vol-was even no effect on supine blood pressure ted with decreases in although it would be advisable, particularly in elderly subjects, to review patients at intervals 139 group.bmj.com on August 24, 2016 -Published by http://heart.bmj.com/ Downloaded from to ensure that supine blood pressure does not subsequently increase. We do not yet know whether it is necessary to give as much as 120 mmol of salt per day. However, until we know otherwise it is reasonable to start with this dose and possibly to reduce it later to a lower maintenance level.
